Literature DB >> 9123854

The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein.

C G Miller1, S N Shchelkunov, G J Kotwal.   

Abstract

Vaccinia virus complement control protein (VCP) is encoded by vaccinia virus, with its homolog encoded by other pathogenic poxviruses including variola virus. Since rodents are the primary reservoir hosts of cowpox virus (CPV) and since CPV encodes a highly conserved functional homolog of VCP, termed here the inflammation modulatory protein (IMP), the effects of injection of CPV into the footpads of mice was determined in order to study the precise in vivo effects of IMP. Macroscopic examination of the site of injection with a recombinant virus lacking IMP (CPV-IMP) showed greater tissue damage, with more hemorrhage and induration, than sites injected with the wild-type cowpox virus. In addition, the measurement of the specific swelling response carried out for several weeks revealed significantly greater swelling in mice injected with CPV-IMP. Thus, IMP modulates the complement-activated inflammatory response in vivo. Furthermore, the diminished destruction of host tissue observed in the presence of IMP indicates symbiosis in which the virus ensures the preservation of surrounding host tissue, possibly to support the growth of its progeny.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9123854     DOI: 10.1006/viro.1996.8396

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  35 in total

1.  Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense.

Authors:  S A Smith; N P Mullin; J Parkinson; S N Shchelkunov; A V Totmenin; V N Loparev; R Srisatjaluk; D N Reynolds; K L Keeling; D E Justus; P N Barlow; G J Kotwal
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Species-specific differences in the organization of the complement-binding protein of orthopoxviruses.

Authors:  S N Shchelkunov; E A Uvarova; A V Totmenin; P F Safronov; L S Sandakhchiev
Journal:  Dokl Biochem Biophys       Date:  2001 Jul-Aug       Impact factor: 0.788

Review 3.  Poxvirus immunomodulatory strategies: current perspectives.

Authors:  J B Johnston; Grant McFadden
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

4.  Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection.

Authors:  Ryan D Estep; Ilhem Messaoudi; Megan A O'Connor; Helen Li; Jerald Sprague; Alexander Barron; Flora Engelmann; Bonnie Yen; Michael F Powers; John M Jones; Bridget A Robinson; Beata U Orzechowska; Minsha Manoharan; Alfred Legasse; Shannon Planer; Jennifer Wilk; Michael K Axthelm; Scott W Wong
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 5.  Complement evasion by human pathogens.

Authors:  John D Lambris; Daniel Ricklin; Brian V Geisbrecht
Journal:  Nat Rev Microbiol       Date:  2008-02       Impact factor: 60.633

Review 6.  The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins.

Authors:  Brian C DeHaven; Kushol Gupta; Stuart N Isaacs
Journal:  J Gen Virol       Date:  2011-06-29       Impact factor: 3.891

Review 7.  Viral-derived complement inhibitors: current status and potential role in immunomodulation.

Authors:  Hadi Abou-El-Hassan; Hassan Zaraket
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-26

Review 8.  Interactions of viruses and the humoral innate immune response.

Authors:  Bailey E Maloney; Krishani Dinali Perera; Danielle R D Saunders; Naemi Shadipeni; Sherry D Fleming
Journal:  Clin Immunol       Date:  2020-02-04       Impact factor: 3.969

9.  Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.

Authors:  Debra C Quenelle; Deborah J Collins; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.